Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer-Reference-Cited by-同舟云学术

Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer

Published:2017-05 Issue:7 Volume:18 Page:597-600
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Ellis Leigh¹²

Affiliation:

1. Department of Oncologic Pathology, Dana-Farber Cancer Institute, Brigham & Women’s Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA

2. Department of Pathology. Brigham & Woman’s Hospital, Harvard Medical School, Boston, MA 02115, USA

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2017-0039

Reference22 articles.

1. Cancer statistics, 2015

2. Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis

3. Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

4. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

5. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer;Cancer Discovery;2024-04-08

2. Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer;2023-12-16

3. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers;2023-10-27

4. Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies;Cancer Reports;2021-02-17

5. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer;Urologic Clinics of North America;2020-11